Abstract YO38
Case summary
Thymomas constitute 10% of mediastinal tumours and are often benign epithelial neoplasms of the thymus gland. Up to a third of cases of thymomas are malignant and causes local infiltration to surrounding structures. Rarely, they metastasize to distant organs. We report a case of slow growing thymoma which progressed into cerebral metastases. A 53 year old lady presented with 5 years history of a mediastinal tumour. She initially refused any therapy at the first presentation. She returned with an enlarging anterior mediastinal mass causing chest pain and cough. Thoracic CT revealed a 10 cm right anterior mediastinal mass abutting the pericardium. Histopathological examination of the mediastinal mass biopsy indicated thymoma. She was planned for surgical resection however developed acute neurological symptoms of headache, confusion and memory loss. Cranial MRI showed multiple lesions in the temporoparietal lobe, left frontal lobe, internal capsule and basal ganglia. Stereotactic biopsy confirmed metastases from a B1 type thymoma. She deteriorated rapidly and died without any possible intervention. Intracranial metastases from thymic tumours are rare. To date, there are 45 cases reported within the literature of cerebral metastases from thymic epithelial tumours. The median survival with multiple cerebral metastases is merely 64 days, hence high suspicion of distant spread in thymic epithelial tumours and prompt surgery may potential improve the outcome in this group of patients.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract